Lipoprotein(a) is one of the most genetically determined risk factors in cardiovascular medicine. Somewhere between 70% and over 90% of the variation in Lp(a) levels from person to person is written into DNA, according to an American Heart Association scientific statement.1PubMed Central. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association That makes Lp(a) fundamentally different from LDL cholesterol or triglycerides, which respond meaningfully to diet, exercise, and standard medications. Your Lp(a) level is largely the level you were born with, and a single gene is mostly responsible.
How Much of Your Lp(a) Level Is Inherited
Twin and family studies have tried to pin down the heritability number. A Dutch parent-twin study found that nearly all the variance in Lp(a) concentrations could be explained by genetics, with heritability estimates of 93% in females and 98% in males.2PubMed. Lipoprotein(a): relation to other risk factors and genetic heritability. Results from a Dutch parent-twin study Those numbers are striking even by the standards of heritable traits. Height, often held up as a strongly genetic characteristic, shows heritability around 80%. Lp(a) surpasses it.
The gene responsible is called LPA, and it sits on chromosome 6. What makes it unusual is a structural feature: a repeating section known as the kringle IV type 2 (KIV-2) domain. The number of these repeats varies enormously from person to person. Some people carry fewer than 10 copies, others more than 40. This copy-number variation is the single largest genetic driver of Lp(a) levels. People with fewer KIV-2 repeats tend to produce a smaller version of the apolipoprotein(a) protein, and their livers clear it more slowly, resulting in higher circulating Lp(a).3PubMed Central. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk People with more repeats produce a larger protein and generally have lower levels.
Beyond the KIV-2 size variation, individual point mutations in and around the LPA gene also matter. One example is the splice-site variant 4925G>A within the KIV-2 region. Researchers investigating whether certain repeat sequences in the LPA promoter region independently affected Lp(a) found that their apparent effect vanished once the 4925G>A variant was accounted for, showing how tightly linked these genetic variants are.4Journal of Lipid Research. Linkage disequilibrium with the KIV-2 variant 4925G>A explains the association of LPA promoter pentanucleotide repeats with lipoprotein(a) concentrations The genetics of Lp(a) are concentrated in and around one gene, but the internal architecture of that gene is remarkably complex.
What Lp(a) Actually Is
Structurally, Lp(a) looks a lot like an LDL particle. It carries cholesterol, it has the same apolipoprotein B100 on its surface that LDL does, and it circulates in the bloodstream in a similar way. The difference is that Lp(a) also carries an additional protein, apolipoprotein(a), attached to the apoB100 by a chemical bond.5PubMed Central. Lipoprotein (a): structure, pathophysiology and clinical implications That extra protein is what makes Lp(a) both genetically distinct and medically dangerous in ways that ordinary LDL is not.
Apolipoprotein(a) bears a remarkable resemblance to plasminogen, a protein the body uses to dissolve blood clots. The resemblance is close enough that Lp(a) can effectively block plasminogen from doing its job. It competes for the same binding sites on fibrin (the mesh that holds clots together) and on cell surfaces, but unlike plasminogen, it cannot actually break anything down.6Atherosclerosis. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis The result is that high Lp(a) makes clots harder to dissolve.7Advances in Lipoprotein(a) Research. The role of lipoprotein (a) in the coagulation/fibrinolysis system during rupture of an atherosclerotic plaque
Combined with its LDL-like ability to deposit cholesterol in artery walls and its capacity to promote inflammation, Lp(a) carries a triple threat: it is pro-atherosclerotic, pro-thrombotic, and pro-inflammatory.8PubMed Central. Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options No other lipoprotein in common clinical use does all three.
The Inheritance Pattern and What It Means for Families
Elevated Lp(a) is inherited as a codominant trait.3PubMed Central. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk In practical terms, each parent contributes one copy of the LPA gene, and both copies influence your Lp(a) level. If one parent has high Lp(a) and the other has low Lp(a), your level will reflect contributions from both, not a simple dominant-versus-recessive outcome. People who inherit two copies of the LPA gene that produce smaller apolipoprotein(a) isoforms will have the highest levels. Someone who carries two different-sized isoforms will have two distinct populations of Lp(a) particles circulating simultaneously.9PubMed Central. Interlaboratory comparison of serum lipoprotein(a) analytical results across clinical assays-Steps toward standardization
This has a direct consequence for family screening. If you have elevated Lp(a), there is a substantial chance your siblings, parents, and children carry a similar genetic profile. Current guidelines from the National Lipid Association recommend cascade screening of first-degree relatives when someone is found to have elevated levels.10PubMed Central. Lipoprotein(a) in Personalized Cardiovascular Prevention: Risk Stratification, Coronary Artery Calcium, and Emerging Lp(a)-Lowering Therapies Unlike many cardiovascular risk factors, elevated Lp(a) cannot be blamed on shared family diets or lifestyles. It follows the gene.
Levels Stabilize Early and Stay Put
One of the more unusual features of Lp(a) is how early in life levels settle into their adult range. Serum concentrations reach a relatively stable value by around age five, even though the LPA gene does not complete its full expression until roughly age 20.11PubMed Central. Lipoprotein(a) in Children and Adolescents: Risk or Causal Factor for Cardiovascular Disease? A Narrative Review After that childhood set-point is established, levels remain relatively steady throughout the rest of life.12PubMed Central. Age-Dependent Clinical Relevance of Lipoprotein(a): A Comprehensive Review from Childhood to Adulthood
This stability reinforces the genetic nature of Lp(a). Most blood lipids fluctuate in response to body weight, diet, medication, and aging. Lp(a) barely budges. A person with a high level at age 10 will almost certainly still have a high level at 60, absent a targeted pharmaceutical intervention. The flip side is also true: if your Lp(a) is low, it is going to stay low, and no amount of unhealthy eating will push it to dangerous levels.
Racial and Ethnic Differences in Lp(a) Levels
Because Lp(a) levels are genetically driven, population-level differences across racial and ethnic groups are substantial and well documented. Black individuals tend to have the highest median concentrations, with published medians ranging from about 27 to 46 mg/dL. White and South Asian populations cluster in the middle. East Asian populations tend to have lower levels, with medians reported between roughly 1 and 13 mg/dL. Hispanic populations also tend toward lower levels, though the data for this group remain limited.13PubMed Central. The impact of Race and Ethnicity on Lipoprotein (a) Levels and Cardiovascular Risk
A large study disaggregating Lp(a) levels across subgroups found that over 62% of non-Hispanic Black patients had Lp(a) levels at or above 50 mg/dL, compared with about 31% of Mexican patients. After statistical adjustment, Black individuals had roughly 2.5 times the odds of having elevated Lp(a) compared with the reference group, while Hispanic and Asian individuals had lower odds.14PubMed Central. Lipoprotein(a) Levels in Disaggregated Racial and Ethnic Subgroups Across Atherosclerotic Cardiovascular Disease Risk Levels
These differences are rooted in evolutionary genetics, not lifestyle or socioeconomic factors. Different ancestral populations carry different distributions of KIV-2 repeat numbers and LPA variants. The clinical implication is that universal risk thresholds may not apply equally across all groups, and clinicians are increasingly recognizing that context matters when interpreting a number.
What High Lp(a) Does to Your Heart and Arteries
Elevated Lp(a) is now considered an independent, causal risk factor for atherosclerotic cardiovascular disease. The evidence has moved well past association and into causation, primarily through Mendelian randomization studies that use genetic variants as natural experiments. People who inherit the genetic profile for high Lp(a) develop more heart disease, even when other risk factors are carefully controlled for.
Among people with familial hypercholesterolemia, who already carry a heavy genetic burden of high LDL, having elevated Lp(a) on top of that roughly doubled the risk of cardiovascular events.15PubMed. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia That finding underscores how Lp(a) operates through mechanisms distinct from standard LDL cholesterol.
Beyond heart attack and stroke risk, Lp(a) has a well-established connection to aortic valve disease. Elevated levels are strongly associated with calcific aortic stenosis, and genetic studies support a causal relationship between lifelong exposure to high Lp(a) and valve calcification.16Nutrition, Metabolism and Cardiovascular Diseases. Lipoprotein(a) and aortic valve stenosis: From pathophysiology to novel therapeutic approaches17PubMed Central. Lipoprotein(a) and calcific aortic stenosis: from inherited risk marker to therapeutic target Aortic stenosis is a progressive condition in which the valve stiffens and narrows over years, eventually restricting blood flow out of the heart. The idea that a genetically fixed lipoprotein is quietly calcifying a heart valve for decades, before symptoms ever appear, is one of the more concerning aspects of high Lp(a).
Why Standard Treatments Do Not Work
Statins, the cornerstone of cholesterol management, do not lower Lp(a). Some evidence suggests they may even raise it slightly in certain patients. Diet and exercise do nothing meaningful to the number. This is the direct practical consequence of Lp(a) being genetically determined: the liver produces it at a rate set by your DNA, and most conventional interventions cannot override that instruction.
There is one partial exception. Estrogen has been shown to reduce Lp(a) levels. In a placebo-controlled crossover study of postmenopausal women, oral estrogen lowered Lp(a) by an average of about 23%.18PubMed. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women This helps explain why Lp(a) levels sometimes rise after menopause. However, prescribing estrogen specifically to lower Lp(a) is not standard practice, because hormone therapy carries its own cardiovascular risks and benefits that have to be weighed independently.
PCSK9 inhibitors, a newer class of injectable drugs designed to lower LDL cholesterol, do modestly reduce Lp(a) as a side effect. In a large trial, the PCSK9 inhibitor evolocumab lowered Lp(a) by a median of about 27%.19PubMed. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk That is a modest dent rather than a transformative reduction, and the effect varies widely between patients. PCSK9 inhibitors are not approved specifically for Lp(a) lowering.
RNA-Based Therapies That Target the Gene Directly
The most promising frontier for treating high Lp(a) is a new class of drugs that work by silencing the LPA gene itself, preventing the liver from manufacturing apolipoprotein(a) in the first place. Several of these are in clinical trials, and the early results have been dramatic.
Olpasiran, a small interfering RNA (siRNA), works by intercepting the messenger RNA that the LPA gene produces, effectively shutting down apo(a) production before the protein is even assembled. In a phase 2 trial, olpasiran reduced Lp(a) levels by 70% to over 100% depending on the dose, with injections needed only every 12 to 24 weeks.20PubMed. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease No significant safety concerns were reported during the trial.21PubMed. Advances in RNA-Based Therapies Targeted at Lipoprotein(a): Olpasiran in the Management of Atherosclerotic Cardiovascular Disease Other RNA-based drugs in development, including pelacarsen, lepodisiran, and SLN360, use similar strategies to block apo(a) production.22PubMed Central. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
The critical unanswered question is whether lowering Lp(a) levels this dramatically will actually reduce heart attacks, strokes, and aortic valve disease. The biology strongly suggests it should, and the genetic evidence for causation is solid, but clinical outcomes trials are still underway. Until those results are in, these drugs are not yet approved for general use. The Lp(a)HORIZON trial is the largest such outcomes study, and its data will likely determine whether Lp(a)-lowering becomes a new pillar of cardiovascular prevention.
Getting Tested and Understanding the Numbers
Multiple major guidelines now recommend that every adult have their Lp(a) measured at least once. The logic is straightforward: since the level is genetically fixed, one measurement tells you what you need to know for life. The 2024 National Lipid Association update, the 2025 European Society of Cardiology focused update, and the 2026 American College of Cardiology guideline all converge on this recommendation.10PubMed Central. Lipoprotein(a) in Personalized Cardiovascular Prevention: Risk Stratification, Coronary Artery Calcium, and Emerging Lp(a)-Lowering Therapies If your level is low, you can set it aside and focus on other risk factors. If it is high, that knowledge reshapes your entire prevention strategy.
One complication: Lp(a) is reported in two different units, milligrams per deciliter (mg/dL) and nanomoles per liter (nmol/L), and converting between them is not straightforward. Because the apolipoprotein(a) protein varies in size from person to person, a mass-based measurement (mg/dL) does not translate cleanly into a particle-count measurement (nmol/L). The commonly used conversion factor of 2.5 is a rough approximation that can be substantially off for individual patients.23Atherosclerosis. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? A more refined formula from the Copenhagen General Population Study performs better, but even it carries meaningful error for some individuals.24Atherosclerosis. Concordance of Lipoprotein(a) measurements in mg/dL and nmol/L: Insights from the Lp(a)HORIZON trial The bottom line is that if your lab reports Lp(a) in mg/dL and your cardiologist’s threshold is in nmol/L, be cautious about simple arithmetic conversions. Ask for a direct measurement in the units your clinician uses.
The measurement problem runs deeper than unit conversion. Because most antibodies used in lab assays react with the repeating KIV-2 structure, and because different people have different numbers of those repeats, the same assay can give systematically different readings for two patients who actually have the same number of Lp(a) particles. Standardization efforts are ongoing, but at the time of this writing, interlaboratory variation remains a real issue.9PubMed Central. Interlaboratory comparison of serum lipoprotein(a) analytical results across clinical assays-Steps toward standardization
An Ancient Gene With a Mysterious Purpose
One of the lingering puzzles about Lp(a) is why the gene exists at all. It was first identified in 1963 by the Norwegian geneticist Kåre Berg, who noticed that some people carried a distinct lipoprotein factor and others did not.25PubMed Central. Lipoprotein (a): a historical appraisal Since then, no one has convincingly established a beneficial function for the protein. Theories have included roles in wound healing and tissue repair, but nothing definitive has stuck.
What is clear from evolutionary analysis is that apolipoprotein(a) evolved from a duplicated copy of the plasminogen gene during primate evolution.26PubMed Central. Convergent evolution of apolipoprotein(a) in primates and hedgehog In a twist that has fascinated geneticists, hedgehogs independently evolved their own version of apolipoprotein(a) from a different domain of the plasminogen gene, a case of convergent molecular evolution.27PubMed. The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a) The fact that two lineages separated by tens of millions of years independently invented something resembling Lp(a) suggests there may be an evolutionary advantage that science has not yet identified, or that the gene was repurposed from an ancestral function that no longer matters in modern humans. Either way, we are left with a particle that poses cardiovascular risk and no clear physiological upside to counterbalance it.
What You Can Do If Your Lp(a) Is High
Until targeted Lp(a)-lowering drugs clear their outcomes trials and reach the market, the clinical strategy for people with elevated Lp(a) focuses on controlling every other modifiable risk factor as aggressively as possible. That means driving LDL cholesterol to lower targets than might otherwise be recommended, managing blood pressure tightly, maintaining a healthy weight, not smoking, and treating diabetes rigorously if present. The reasoning is additive risk: you cannot remove the Lp(a) component yet, so you shrink every other contributor to keep the total risk manageable.
Knowing your Lp(a) status also changes how ambiguous clinical decisions get made. A person with borderline indications for a statin might be tipped into treatment if their Lp(a) is elevated, because their true lifetime risk is higher than a standard calculator would predict. Coronary artery calcium scoring can help refine risk further. And if you have high Lp(a), telling your family members to get tested is one of the most straightforward pieces of preventive advice in medicine. The trait travels through families as reliably as eye color, and knowing about it opens the door to earlier and more aggressive prevention.